News & Updates

Show Multimedia Only

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

a day ago by

A 65-year-old male with good past health presented in June 2024 with a 1-month history of cough.

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

a day ago

BTK inhibitor monotherapy in a patient with treatment-naïve CLL

14 Aug 2025 by

A 66-year-old female presented with bilateral cervical lymphadenopathy in January 2022. She had type 2 diabetes mellitus, hypertension and hyperlipidaemia. Blood tests showed haemoglobin (Hb) level of 12.6 g/dL, white blood cell (WBC) count of 75.2 x 10⁹/L, lymphocyte count of 67.6 x 10⁹/L, and platelet count of 214 x 10⁹/L. She was asymptomatic with a baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 0.

BTK inhibitor monotherapy in a patient with treatment-naïve CLL

14 Aug 2025

Transforming outcomes in patients with FLT3-mutated AML

14 Aug 2025 by

Due to its aggressive nature, high relapse rates, and poor survival outcomes, acute myeloid leukaemia (AML) with FMS-like tyrosine kinase 3 (FLT3) gene mutation continues to present significant treatment challenges despite use of targeted therapy. At an industry-sponsored meeting, Dr Richard Dillon from Guy’s Hospital, King’s College London, London, UK, reviewed evolving management practices for patients with FLT3-mutated AML, including unmet needs in the first-line and relapsed/refractory (R/R) settings, and discussed the role of measurable residual disease (MRD)–guided intervention.

Transforming outcomes in patients with FLT3-mutated AML

14 Aug 2025

Early use of ADC in HR-positive, HER2-low metastatic breast cancer with visceral crisis

14 Aug 2025 by

A 39-year-old woman presented in February 2023 with lower-back pain that had persisted since November 2022. She also noted a palpable and painful right breast mass since 2021, but did not seek consultation earlier due to the COVID-19 pandemic.

Early use of ADC in HR-positive, HER2-low metastatic breast cancer with visceral crisis

14 Aug 2025

1L use of a bispecific antibody in a patient with EGFR exon 20 insertion mutation NSCLC

13 Aug 2025 by

A 62-year-old homemaker, who never smoked, with no known family history of cancer and good past health, presented in January 2024 with cough for 7 months post–COVID-19, progressive weight loss over 2 months, and recent-onset left chest pain. Chest X-ray (CXR) showed left pleural effusion, which was drained at a public hospital, with effusion cytology confirming lung adenocarcinoma with EGFR exon 20 insertion (ex20ins) by Sanger sequencing.

1L use of a bispecific antibody in a patient with EGFR exon 20 insertion mutation NSCLC

13 Aug 2025

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

Modern management of BRAFV600E-mutant mCRC

22 Jul 2025 by

Dr Su-Pin Choo of the National Cancer Centre in Singapore shares a BRAF^V600E-mutant metastatic colorectal cancer (mCRC) patient case from her clinical practice and offers practical insights during a Q&A session at an industry-sponsored symposium.

Modern management of BRAFV600E-mutant mCRC

22 Jul 2025

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

27 Jun 2025 by

Despite positive outcomes with the KEYNOTE-522 regimen for triple-negative breast cancer (TNBC), its implementation faces challenges due to resource constraints in Hong Kong’s public healthcare system. Consultant Dr Thomas Kwan-Hang Lau and Resident Dr Kang Li of the Department of Clinical Oncology at Prince of Wales Hospital (PWH) shared insights and a case series on the use of Q3W and Q1W chemotherapy for the KEYNOTE-522 regimen in PWH and explored alternative neoadjuvant chemotherapy options.

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

27 Jun 2025

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

26 Jun 2025 by

Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, shares key insights from TITAN and OASIS studies and highlights the association between PSA response and survival outcomes.

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

26 Jun 2025

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC

12 Jun 2025 by

The third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib, is preferred over earlier-generation EGFR TKIs as the first-line agent in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). In an interview with MIMS Oncology, Dr James Ho, Specialist in Respiratory Medicine in Hong Kong, discussed the positive survival outcomes associated with first-line treatment with osimertinib plus chemotherapy together in patients with advanced EGFR-mutated NSCLC, and shared which patients may benefit from this upfront combination treatment strategy.

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC

12 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

BTK inhibitor monotherapy in a patient with treatment-naïve CLL

BTK inhibitor monotherapy in a patient with treatment-naïve CLL

Transforming outcomes in patients with FLT3-mutated AML

Transforming outcomes in patients with FLT3-mutated AML

Early use of ADC in HR-positive, HER2-low metastatic breast cancer with visceral crisis

Early use of ADC in HR-positive, HER2-low metastatic breast cancer with visceral crisis

1L use of a bispecific antibody in a patient with EGFR exon 20 insertion mutation NSCLC

1L use of a bispecific antibody in a patient with EGFR exon 20 insertion mutation NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Modern management of BRAFV600E-mutant mCRC

Modern management of BRAFV600E-mutant mCRC

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC